A recent study reveals that people who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt conventional diet and exercise plans.
Findings released in a prominent health publication demonstrates that while overweight individuals frequently drop about a fifth of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying these drugs need to be aware of the danger of fast weight regain when the therapy concludes," stated expert Dr. Susan Jebb.
That rate of recovery suggests a return to original mass in about one and a half years.
Analyzing Approaches
The research, which reviewed 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
Scientists point out that individuals who shed pounds through diet and exercise typically see a slower creep back—perhaps 0.1 kg a month—after stopping.
The Reason for the Rapid Regain
Nutrition scientists suggest the mechanism of the injections is key to understanding the heightened weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication results in appetite is unsuppressed, making excessive eating a significant risk."
A Lifelong Disease?
Medical guidelines recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals say that, due to the significant potential of weight regain, the treatment is often ongoing.
This view is reinforced by drug manufacturers, who say that the results "emphasize the persistent character of excess weight," similar to managing conditions like hypertension.
User Accounts
People who have come off the medication describe a intense return of hunger.
"It was like a trigger activating and I was suddenly starving," recalled an individual.
This difficulty is compounded if patients have not established sustainable dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among females than males.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and lasting health benefits relies on ongoing lifestyle changes.
